MAPT and Alzheimer disease: Finally, the diagnostic performance was evaluated by comparing the discriminative power (sensitivity and specificity) of significant inflammatory markers with that of standard AD amyloid and tau biomarkers to discriminate across the three groups in pairwise comparisons.